Dupixent® ( dupilumab ) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid ( BP ) Positive Pivotal Trial
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease. five times more patients achieved sustained disease remission with Dupixent than placebo ...
| Ticker |
Sentiment |
Impact |
|
REGN
|
Neutral
|
3 %
|
|
SNY
|
Neutral
|
10 %
|
